NCT03780426 is a Phase 2 clinical trial of tSMS in Essential Tremor, sponsored by Fundación de investigación HM.

Who is sponsoring NCT03780426?

NCT03780426 is sponsored by Fundación de investigación HM.

What drugs are being tested in NCT03780426?

Interventions in NCT03780426: tSMS, sham.

What condition does NCT03780426 study?

NCT03780426 studies Essential Tremor.

Is NCT03780426 still recruiting?

NCT03780426 is currently completed. Last updated 6 June 2022.

Last reviewed 2022-06-06 · How we verify

NCT03780426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tSMS in Essential Tremor

Completed Phase 2 Last updated 6 June 2022

What this trial tests

Phase 2 trial testing tSMS in Essential Tremor in 30 participants. Completed in 1 December 2019.

Timeline

1 October 2018

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Fundación de investigación HM
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	30
Start date	1 October 2018
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across Spain

Drugs / interventions tested

tSMS
sham

Conditions studied

Essential Tremor — all drugs for Essential Tremor →

Sponsor

Fundación de investigación HM — full company profile →

Who can join

Adults 18 to 80, any sex, with Essential Tremor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is randomized double-blind study to study the hypothesis that transcranial static magnetic field stimulation of the primary motor cortex improves tremor in patients with essential tremor. Half of the patients will receive tSMS of the left hemisphere and the other half of the right hemisphere.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Emerging Therapeutic Targets for Essential Tremor: A Critical Appraisal of Recent Preclinical and Clinical Studies.
Mukherjee A, Pandey S. · · 2025 · cited 5× · PMID 40415659 · DOI 10.1002/mdc3.70147
Transcranial static magnetic field stimulation of the primary motor cortex in essential tremor: a randomized pilot study.
Urso D, Monje MHG, Fernández-Rodríguez B, Vela-Desojo L, et al · · 2025 · cited 1× · PMID 41298510 · DOI 10.1038/s41531-025-01182-x

Verify or expand the search:

Other trials of tSMS

Trials testing the same drug.

NCT05260190 — Manual Dexterity Modifications After Application of tSMS Over the Primary Motor Cortex (M1) · NA · unknown

Other recruiting trials for Essential Tremor

Currently open trials in the same condition.

NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07172295 — Modulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With R · NA · recruiting
NCT07016425 — Temporal Interference for Essential Tremor · NA · recruiting
NCT07049003 — Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor · Phase 1 · recruiting
NCT06428526 — Impact of Sensory Electrical Stimulation on Sensation and Tremor · NA · active not recruiting

Other Fundación de investigación HM trials

Trials by the same sponsor.

NCT05914051 — PRELOAD-TAVI Trial · NA · unknown
NCT06840678 — Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease · Phase 1 · recruiting
NCT05513755 — Cardioneuroablation in Reflex Syncope (CARDIOSYRE Trial) · NA · unknown
NCT04692116 — Parkinson's Disease (PD) Treated With Focused Ultrasound Subthalamotomy at an Early Stage · NA · completed
NCT04525638 — A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03780426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación de investigación HM
Last refreshed: 6 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing